The FDA has approved Sunharbo (asundexian), Bayer's once-daily pill to lower the risk of another stroke in adults who recently had a mild-to-moderate ischemic stroke or a high-risk mini-stroke. It is the first approved factor XIa inhibitor, a new type of blood thinner designed to stop harmful clots while limiting bleeding. The approval rests on the OCEANIC-STROKE trial of 12,327 patients, which found fewer repeat strokes without a significant rise in major bleeding. Sunharbo is taken alongside standard antiplatelet medicines. Doctors welcomed the option but say cost and insurance access could slow early use.
People who survive a stroke face a high risk of having another one soon after. A newly approved pill offers a different way to lower that risk.
How it works
Sunharbo blocks factor XIa, a clotting protein thought to drive dangerous clot growth more than the body's normal ability to stop bleeding. That is why researchers hope this drug class can prevent strokes with fewer bleeding problems than older blood thinners.
The evidence
In the OCEANIC-STROKE trial, patients taking Sunharbo with standard antiplatelet therapy had fewer recurrent ischemic strokes than those on placebo. Gastrointestinal bleeding was somewhat more common, but major bleeding did not rise significantly.
- Approved: November 2026
- Dose: one 50 mg tablet daily
- Who it's for: adults after a recent non-cardioembolic ischemic stroke or high-risk TIA
- Trial size: 12,327 patients
What to know
This is general news, not medical advice. Anyone who has had a stroke or mini-stroke should talk with their doctor about whether a new treatment is right for them.
Related on MiniGoogle
- NASA Launches $1 Million Challenge for Students to Help Design a Moon Base
- Muslims Projected to Become the World's Largest Religious Group by 2035, Pew Finds
- More Health news
Sources
MiniGoogle summarizes reporting from the outlets above in our own words. Figures are as reported at the time of publication.
